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COMMENTARYFood and Drug Administration commentary on ‘‘A new paradigm
for obtaining marketing approval for pediatric-sized prosthetic
heart valves’’Fernando Aguel, MSE, Steven B. Kurtzman, MD, Sonna Patel-Raman, PhD,
Matthew Hillebrenner, MSE, and Bram D. Zuckerman, MDIn January 2010, the US Food and Drug Administration
(FDA) and AdvaMed organized a workshop for developing
a pathway to market for pediatric heart valves. This meeting
included representatives from the device industry, medical
community, academia, and the FDA. It resulted in a detailed
pathway for gaining market approval for pediatric-sized
heart valves to address the unmet need for these heart
valves.
The article titled, ‘‘A new paradigm for obtaining market-
ing approval for pediatric-sized prosthetic heart valves,’’
by Yoganathan and colleagues, presents this pathway to eval-
uate the safety and effectiveness of specific types of pediatric
heart valves.1 In particular, this pathway is presented for
smaller sizes of surgically implanted heart valves that already
have premarket approval in the United States, comprising the
samematerials andmanufactured by the same processes, and
could be reviewed through a premarket approval supplement
application.
The underlying theme of this pathway is leveraging our
existing knowledge about adult-sized heart valves and en-
couraging a more global approach for future device devel-
opment. A key component of this pathway is the total
product life cycle approach, with which we can leverage
the many facets of the review process to bring these devices
to market. With this approach, accelerated wear testing, hy-
drodynamic testing, flow visualization analysis, and kine-
matic assessment would be conducted for the new valve
sizes. If the new valve size represents worst-case loading
conditions, new fatigue testing would also be conducted.
Because the new sized valve has the same design and is
made of the same materials, however, new animal testing
and testing for biocompatibility and sterilization would
not need to be conducted. Because there is also presumably
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position (eg, aortic, mitral) would typically be expected for
the clinical trial. A postapproval study would be conducted
to assess the long-term safety and effectiveness of the new
pediatric-sized valves.
Although the FDA generally defines pediatric subgroups
differently (newborn or neonate from birth to 1 month of
age; infant older than 1 month to 2 years of age; child older
than 2 years to 12 years of age; and adolescent older than 12
years to 21 years of age)2 than the classification presented in
this article, the age brackets outlined by Yoganathan and
colleagues were determined by the clinical subgroup at
the FDA-AdvaMed workshop as age groupings with differ-
ent physiologic conditions. The workshop preclinical team
used these conditions to outline the recommended testing
conditions for hydrodynamic testing, accelerated wear test-
ing, and loading conditions to be used in any fatigue testing
conducted as part of this approach.
The approach presented in the article is consistent with
FDA’s regulatory practices for surgically implanted heart
valves, is capable of providing a reasonable assurance of
safety and effectiveness, promotes pediatric device devel-
opment, and represents the least burdensome approach to
the important unmet need of pediatric heart valves.References
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